Promising collaboration to revolutionize CKD treatment

We are delighted to announce that our NephroGuard project has been selected as one of the experimental projects of Tiers-lieu Unirein, a consortium of excellence bringing together the best experts in the field of kidney disease. This collaboration marks an important step forward in our mission to optimize the management of CKD thanks to the innovative digital solutions developed by Bio Logbook.

Unirein: A catalyst for innovation in kidney disease

The Tiers-lieu Unirein is an ambitious initiative aimed at transforming the management of renal and metabolic diseases in France. This unique hub brings together key players in the sector, such as researchers, clinicians, manufacturers and patients, around a common goal: to accelerate the development and adoption of innovative solutions to improve the quality of life of CKD patients.

NephroGuard: A digital solution for patients

NephroGuard is a digital solution designed to support CKD patients in their care. This intuitive platform enables patients to track their health status in real time, receive personalized advice and connect with their medical team. NephroGuard has already demonstrated its effectiveness in improving patient health outcomes and reducing healthcare costs.

A promising collaboration for the future

Our participation in the Tiers-lieu Unirein will enable us to benefit from an environment conducive to innovation, and to collaborate closely with world-renowned experts. We are convinced that this collaboration will accelerate the development of NephroGuard and make it a key solution for the management of CKD in France.

A revolutionary patented methodology

The study, entitled " A novel methodology for calculating optimized and personalized reference populations of biological parameters", presents a patented methodology developed by Bio Logbook for calculating optimized and personalized reference populations of biological parameters. This innovative methodology enables more accurate and relevant results to be obtained for patient diagnosis and follow-up, paving the way for more personalized, high-performance medicine.

Recognized scientific impact

The publication of this study in CCA Clinica Chimica Acta, a leading scientific journal in the field of clinical chemistry, testifies to the quality and scientific impact of Bio Logbook's work. This international recognition positions the company as a major player in the development of innovative solutions to improve patient care.

Tribute to contributors

Ronan Boutin, President and Founder of Bio Logbook, would like to express his deep gratitude to all the people and institutions who have contributed to this success:

INOVIE (Groupe), and in particular Dr Bruno Gauthier and Dr Pierre-Jean Lamy, for their invaluable contribution.

CHU de Liège: Pr. Philippe Kolh, Pr. Michel Moutschen; Dr. Nathalie Maes, Marie Thys_Marie

Prof. ALBERT Adelin for his invaluable support and patience.

Clément Bézier for his excellent editorial work and fine-tuning of the publication.

Jakez Rolland and Marie Codet for their proofreading and production of analyses and graphs.

A new milestone

The publication of this scientific study marks a new milestone for Bio Logbook. The company is determined to pursue its research and develop new innovative solutions to improve patient health.

"This publication is an important milestone for Bio Logbook," says Ronan Boutin. "It confirms the scientific value of our work and encourages us to continue our efforts to develop innovative solutions that contribute to improving patient care."

Data characterization: a crucial issue for healthcare

Data analysis and interpretation are at the heart of many scientific fields, and healthcare is no exception. To fully exploit the potential of biological and medical data, it is essential to characterize them accurately and thoroughly. This is the background to Jakez Rolland's work.

Topology, geometry and multidimensional structure: an innovative approach

In his research paper, Jakez Rolland proposes an innovative approach to characterizing data based on its topology, geometry and multidimensional structure. This approach captures valuable information on the relationships and interactions between data, opening up new perspectives for the analysis and interpretation of biological and medical data.

Towards more personalized medicine and unrivalled predictive capabilities

The potential applications of this approach are numerous and promising. In particular, it could contribute to the development of more accurate diagnostic and prognostic models, the identification of relevant biomarkers for patient management, and the development of personalized therapies.

Thanks to the thesis supervisors

Bio Logbook would like to warmly thank Benoit Delahaye and Damien Eveillard, the supervisors of Jakez Rolland's thesis, for their invaluable support and essential contribution to this research work.

A strong commitment to ethical and responsible AI.

AI's Human Guarantee: a crucial issue

In the context of a proliferation of AI-based software in many fields, the question of AI's human guarantee is becoming a crucial issue, particularly in the sensitive field of healthcare. It is indeed essential to ensure that these technologies are developed and used ethically and responsibly, taking into account human and societal aspects.

An innovative approach at the heart of medical biology

That's why, at BioLogbook, we've chosen to take an innovative approach to AI by subscribing to the principles of the AI Human Guarantee. In collaboration with Ethik IA, a consultancy specializing in the ethics of artificial intelligence, and SFIL, we have set up a pilot project aimed at guaranteeing permanent human supervision of our AI software dedicated to medical biology.

An exemplary partnership in the service of ethics

This pilot project is part of an exemplary partnership between BioLogbook, Ethik IA and SFIL. We would like to extend our warmest thanks to the Ethik IA team, and in particular David Gruson and Emilie SENEGAS, for their invaluable expertise and commitment. We would also like to thank Eric LAINE, Chairman of SFIL, and the entire SFIL team, in particular Manuela MÉMIN and Bruno Gauthier, for their support and active collaboration.

A strong commitment to the future

The launch of this pilot project marks an important step in our commitment to ethical and responsible AI in medical biology. We are convinced that the AI Human Guarantee is an essential element in guaranteeing the trust and safety of patients and healthcare professionals.

We will continue to work actively with our partners to advance the responsible use of AI in healthcare, contributing to better, more humane medicine.

Data vs COVID-19 Game on!

Technological solutions have a role to play against COVID-19, and they are multiplying. With this in mind, the COVID-X research and innovation program (H2020), supported by the European Commission, launched the "Data vs COVID-19 game on" call for projects to support the best of them. 16 projects from all over Europe, alone or in teams, were rewarded out of more than a hundred, including Bio Logbook - the only French start-up to win - in a team with Liège University Hospital, for the detection of patients at highest risk of developing the disease.

COVID-X provides funding of up to 150,000 euros, including 100,000 euros for the start-up and 50,000 euros for the medical institution responsible for helping the company validate the innovation. The European program also supports the winners with a 10-month acceleration program on various themes: regulatory mentoring, market, ethics and technical issues, and access to a health data protection and analysis tool. The aim is to optimize the organization of medical care through the use of technological tools, and thus limit the workload for caregivers.

Personalized, customized patient care

Bio Logbook has developed a multi-parametric algorithm for patient complication risk, using the first laboratory test performed after the PCR test. Practitioners are thus guided more quickly to the patients most at risk, and save time thanks to optimized care organization. Patients, in turn, receive the right care at the right time.

Indeed, the extreme velocity of the disease means that personalized care is required, with a global and detailed overview of the patient's state of health as soon as he or she arrives at the hospital. The analysis of all the patient's biological measurements and clinical results takes up a great deal of time for practitioners and care teams, so the subject is strategic for dealing with this COVID-19 crisis.

Bio Logbook has adapted its early imbalance detection and prediction software to the COVID-19 issue. The proposed results are centered around 3 pillars:

• Monitoring of measured biological parameters :
  • Calculation of customized early biological drifts
  • Identifying biological parameters predictive of complication risk
  • Graphical monitoring of personalized disease progression for each biological parameter, enabling variations within reference thresholds to be read off.

• Detection of additional biological parameters to be monitored:
  • Help in prescribing prognostic biological parameters to be monitored
  • Identification of biological parameters linked to complication risk

• The prognosis of patients' risk of developing a severe form of COVID-19.

CHU de Liège and Bio Logbook, a more global partnership

In December 2018, they contracted a collaboration relating to the academic validation of the method developed by Bio Logbook as part of the European Boost4Health program. It includes the provision of a dataset and academic expertise in bio statistics. The mission is to use an external biological database to scientifically validate the claims of the patent developed by Bio Logbook. The partnership has been extended within the framework of COVID-19 in order to detect upstream those patients most at risk in relation to patients whose state of health is about to stabilize. This includes the development of a diagnostic guidance algorithm specific to COVID-19, based on the analysis of personalized biological drifts. The objectives are to prevent the pathology from developing unfavorably, to focus efforts on at-risk patients and to relieve overcrowding in intensive care units.